Rebisufligene etisparvovec
- Generic Name
- Rebisufligene etisparvovec
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1966978-67-5
- Unique Ingredient Identifier
- V28L3Q0LVZ
- Associated Conditions
- -
- Associated Therapies
- -
Gene Transfer Study of ABO-102 in Patients With Middle and Advanced Phases of MPS IIIA Disease
Phase 1
Terminated
- Conditions
- Interventions
- First Posted Date
- 2019-09-13
- Last Posted Date
- 2023-07-25
- Lead Sponsor
- Ultragenyx Pharmaceutical Inc
- Target Recruit Count
- 5
- Registration Number
- NCT04088734
- Locations
- 🇺🇸
Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania, United States
🇦🇺Adelaide Women's and Children's Hospital, North Adelaide, South Australia, Australia
🇪🇸Hospital ClÃnico Universitario de Santiago, Santiago De Compostela, Spain
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath